PL-9643 is a synthetic peptide commercialized by Palatin Technologies, with a leading Phase III program in Keratoconjunctivitis Sicca (Dry Eye). According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of PL-9643’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for PL-9643 is expected to reach an annual total of $332 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
PL-9643 Overview
PL-9643 is under development for the treatment of dry eye, uveitis. It is administered through ophthalmic route as solution. The therapeutic candidate acts by targeting melanocortin receptor 1 and 5. It is developed based on MIDAS technology.
The drug candidate was under development for the treatment of diabetic retinopathy and inflammatory bowel disease.
Palatin Technologies Overview
Palatin Technologies (Palatin) is a biopharmaceutical company. It is focused on developing therapeutics targeting the melanocortin receptor (MCr) system, which is vital for functions like inflammation and metabolism. The company focuses on obesity and male sexual dysfunction, recently launching a Phase 2 trial for bremelanotide combined with tirzepatide to enhance weight loss efficacy. Palatin is working on a co-formulated bremelanotide with a PDE5 inhibitor for erectile dysfunction. Its lead candidate, PL9643, targets dry eye disease, with a successful Phase 3 trial underway. The company is also conducting a Phase 2 study for PL8177, targeting inflammatory bowel diseases, while also progressing with research for diabetic nephropathy and diabetic retinopathy. Palatin is headquartered in Cranbury, New Jersey, the US.
The company reported revenues of (US Dollars) US$4.5 million for the fiscal year ended June 2024 (FY2024), a decrease of 7.5% over FY2023. The operating loss of the company was US$22.5 million in FY2024, compared to an operating loss of US$32.5 million in FY2023. The net loss of the company was US$29.7 million in FY2024, compared to a net loss of US$24 million in FY2023.
For a complete picture of PL-9643’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.